Cargando…

Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021

SIMPLE SUMMARY: In operated pancreatic cancer patients who are able to begin treatment within 3 months after surgery, adjuvant chemotherapy is currently used to limit disease recurrence but questions remain for the clinician. Recently, modified FOLFIRINOX has become the standard-of-care in the non-A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turpin, Anthony, el Amrani, Mehdi, Bachet, Jean-Baptiste, Pietrasz, Daniel, Schwarz, Lilian, Hammel, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767489/ https://www.ncbi.nlm.nih.gov/pubmed/33371464 http://dx.doi.org/10.3390/cancers12123866

Ejemplares similares

Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
por: Turpin, Anthony, et al.
Publicado: (2022)

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2018)

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2020)

Localized Small Bowel Adenocarcinoma Management: Evidence Summary
por: Turpin, Anthony, et al.
Publicado: (2022)

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

COVID 19 et cancer : quelles sont les conséquences de la réorganisation des soins oncologiques ?
por: El Amrani, Mehdi, et al.
Publicado: (2020)

Le ‘’COVID-Sleep’’ des chirurgiens…. Jusqu’à quand?
por: Amrani, Mehdi El, et al.
Publicado: (2020)

Treatment of Pancreatic Cancer: What Can We Really Predict Today?
por: Bachet, Jean-Baptiste, et al.
Publicado: (2011)

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
por: Nicolle, R., et al.
Publicado: (2021)

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Pernot, Simon, et al.
Publicado: (2016)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

A novel technique for reducing pancreatic fistulas after pancreaticojejunostomy
por: Subar, Daren, et al.
Publicado: (2015)

Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features
por: Raffenne, Jérôme, et al.
Publicado: (2021)

Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
por: Lee, Jee-Soo, et al.
Publicado: (2019)

Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors
por: Bachet, Jean-Baptiste, et al.
Publicado: (2010)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights
por: Mas, Léo, et al.
Publicado: (2021)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
por: Javed, Sahir, et al.
Publicado: (2022)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)
por: Brugel, Mathias, et al.
Publicado: (2022)

Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma
por: Saillard, Charlie, et al.
Publicado: (2023)

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives
por: Pekarek, Leonel, et al.
Publicado: (2021)

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
por: Debbabi, Inès, et al.
Publicado: (2023)

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
por: Brouquet, Antoine, et al.
Publicado: (2020)

A novel event-free survival endpoint in locally advanced pancreatic cancer
por: Hammel, Pascal, et al.
Publicado: (2021)

Editors’ note: 2021 Special Issue on airway management
por: Schwarz, Stephan K. W., et al.
Publicado: (2021)

Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
por: Neuzillet, Cindy, et al.
Publicado: (2023)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction?
por: Moryoussef, Frédérick, et al.
Publicado: (2017)

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
por: Taieb, Julien, et al.
Publicado: (2023)

Towards Sustainable Green Adjuvants for Microbial Pesticides: Recent Progress, Upcoming Challenges, and Future Perspectives
por: Lin, Fuyong, et al.
Publicado: (2023)

Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples
por: Bachet, Jean-Baptiste, et al.
Publicado: (2013)

Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial
por: Neuzillet, Cindy, et al.
Publicado: (2015)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
por: Lambert, Aurélien, et al.
Publicado: (2021)

Towards evidence-based practice in the social services and older people care: from the line managers’ perspective
por: Mosson, Rebecca, et al.
Publicado: (2014)

Acute pancreatitis: current perspectives on diagnosis and management
por: Shah, Adarsh P, et al.
Publicado: (2018)

Bioactivity of Polyphenols: Preventive and Adjuvant Strategies toward Reducing Inflammatory Bowel Diseases—Promises, Perspectives, and Pitfalls
por: Kaulmann, Anouk, et al.
Publicado: (2016)

An update on treatment options for pancreatic adenocarcinoma
por: Lambert, Aurélien, et al.
Publicado: (2019)

Adjuvant chemotherapy in elderly patients with pancreatic cancer
por: Nagrial, A M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ren9bib1vi0ci1d5ircods05q9